Using engineered probiotics to treat autoimmune diseases
Engineered probiotic for the treatment of autoimmune diseases
This study is exploring a new way to help people with autoimmune diseases by using a special probiotic that can be taken by mouth, which delivers helpful proteins to calm down the immune system, making treatment easier and more comfortable than current injections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11030844 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating autoimmune diseases by using a specially engineered probiotic that can deliver therapeutic peptides orally. The study focuses on developing a strain of Lactobacillus reuteri that produces an immunomodulatory peptide designed to inhibit the activation of T lymphocytes, which play a key role in autoimmune responses. By providing a non-invasive treatment option, the research aims to improve patient compliance and therapeutic outcomes compared to current injectable biologics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune diseases such as rheumatoid arthritis or multiple sclerosis.
Not a fit: Patients with autoimmune diseases who are not responsive to probiotic treatments or those who require immediate intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more convenient and effective treatment option for patients with autoimmune diseases, reducing the need for frequent injections.
How similar studies have performed: Other research has shown promise in using engineered probiotics for therapeutic purposes, indicating potential for success in this novel approach.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Beeton, Christine — Baylor College of Medicine
- Study coordinator: Beeton, Christine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.